{"id": "article-30391_0", "title": "Valproate Toxicity -- Continuing Education Activity", "content": "Valproate toxicity results from an excessive accumulation of valproic acid in the body, often triggered by factors like high dosages, rapid dose adjustments, or interactions with other medications. Symptoms vary widely, including gastrointestinal distress symptoms such as nausea and vomiting, neurological manifestations like drowsiness, confusion, and, in severe cases, coma or fatality. Timely identification of risk factors and early symptom recognition is pivotal for intervening and mitigating adverse consequences. Treatment strategies involve a multifaceted approach, including supportive care to manage symptoms and specific interventions like L-carnitine therapy or hemodialysis to remove excess valproic acid from the bloodstream.", "contents": "Valproate Toxicity -- Continuing Education Activity. Valproate toxicity results from an excessive accumulation of valproic acid in the body, often triggered by factors like high dosages, rapid dose adjustments, or interactions with other medications. Symptoms vary widely, including gastrointestinal distress symptoms such as nausea and vomiting, neurological manifestations like drowsiness, confusion, and, in severe cases, coma or fatality. Timely identification of risk factors and early symptom recognition is pivotal for intervening and mitigating adverse consequences. Treatment strategies involve a multifaceted approach, including supportive care to manage symptoms and specific interventions like L-carnitine therapy or hemodialysis to remove excess valproic acid from the bloodstream."}
{"id": "article-30391_1", "title": "Valproate Toxicity -- Continuing Education Activity", "content": "Through this course, participants better understand valproate toxicity comprehensively, including proficient identification of risk factors, thorough patient assessment techniques, and implementing appropriate diagnostic and therapeutic measures. Additionally, collaborating with an interprofessional team is emphasized, as this enhances patient outcomes significantly by facilitating seamless communication and coordination across various healthcare disciplines. By leveraging the expertise and resources of diverse specialists, patient care\u00a0is optimized, ensuring timely and targeted interventions that improve safety and clinical effectiveness.", "contents": "Valproate Toxicity -- Continuing Education Activity. Through this course, participants better understand valproate toxicity comprehensively, including proficient identification of risk factors, thorough patient assessment techniques, and implementing appropriate diagnostic and therapeutic measures. Additionally, collaborating with an interprofessional team is emphasized, as this enhances patient outcomes significantly by facilitating seamless communication and coordination across various healthcare disciplines. By leveraging the expertise and resources of diverse specialists, patient care\u00a0is optimized, ensuring timely and targeted interventions that improve safety and clinical effectiveness."}
{"id": "article-30391_2", "title": "Valproate Toxicity -- Continuing Education Activity", "content": "Objectives: Screen patients for valproate toxicity, particularly hypoalbuminemic individuals or those exhibiting persistent symptoms despite normal total valproate levels. Implement appropriate diagnostic and therapeutic measures for patients suspected of valproate toxicity, such as obtaining unbound valproate levels and initiating L-carnitine therapy or hemodialysis when indicated. Differentiate between symptoms of valproate toxicity and other medical conditions to facilitate accurate diagnosis and timely intervention. Collaborate with interprofessional teams to ensure comprehensive patient care, leveraging expertise from various specialties to optimize outcomes. Access free multiple choice questions on this topic.", "contents": "Valproate Toxicity -- Continuing Education Activity. Objectives: Screen patients for valproate toxicity, particularly hypoalbuminemic individuals or those exhibiting persistent symptoms despite normal total valproate levels. Implement appropriate diagnostic and therapeutic measures for patients suspected of valproate toxicity, such as obtaining unbound valproate levels and initiating L-carnitine therapy or hemodialysis when indicated. Differentiate between symptoms of valproate toxicity and other medical conditions to facilitate accurate diagnosis and timely intervention. Collaborate with interprofessional teams to ensure comprehensive patient care, leveraging expertise from various specialties to optimize outcomes. Access free multiple choice questions on this topic."}
{"id": "article-30391_3", "title": "Valproate Toxicity -- Introduction", "content": "The valproate ion is the therapeutically active substance in valproic acid, sodium valproate, and divalproex. [1] Valproate is commonly used for generalized and partial seizures, bipolar disorders, schizoaffective disorders, neuropathic pain, and migraine prophylaxis. [2] Valproate toxicity can occur accidentally and intentionally. Toxicity is most likely to occur with dose ramping, in hypoalbuminemia, from drug-drug interactions, or in attempts to cause self-harm.", "contents": "Valproate Toxicity -- Introduction. The valproate ion is the therapeutically active substance in valproic acid, sodium valproate, and divalproex. [1] Valproate is commonly used for generalized and partial seizures, bipolar disorders, schizoaffective disorders, neuropathic pain, and migraine prophylaxis. [2] Valproate toxicity can occur accidentally and intentionally. Toxicity is most likely to occur with dose ramping, in hypoalbuminemia, from drug-drug interactions, or in attempts to cause self-harm."}
{"id": "article-30391_4", "title": "Valproate Toxicity -- Introduction", "content": "Patients with acute valproate overdose\u00a0typically experience hyperammonemia, encephalopathy, and hepatotoxicity. Symptoms consistent with severe valproate overdose include hypotension, tachycardia, respiratory depression, metabolic acidosis, cerebral edema, and valproate-related\u00a0hyperammonemic\u00a0encephalopathy.", "contents": "Valproate Toxicity -- Introduction. Patients with acute valproate overdose\u00a0typically experience hyperammonemia, encephalopathy, and hepatotoxicity. Symptoms consistent with severe valproate overdose include hypotension, tachycardia, respiratory depression, metabolic acidosis, cerebral edema, and valproate-related\u00a0hyperammonemic\u00a0encephalopathy."}
{"id": "article-30391_5", "title": "Valproate Toxicity -- Etiology", "content": "Valproate toxicity commonly occurs when ramping up the dose to achieve\u00a0a therapeutic effect. Valproate toxicity may also occur when free or unbound drug levels become elevated. Elevated free drug concentrations are\u00a0common\u00a0in older patients and patients with hypoalbuminemia, and also in those who are pregnant, have renal dysfunction, liver disease, or in those who use medications that compete with valproate for albumin binding sites. [3] Additionally, patients who intentionally overdose on valproate during attempts of\u00a0self harm\u00a0experience varying degrees of valproate toxicity. [4]", "contents": "Valproate Toxicity -- Etiology. Valproate toxicity commonly occurs when ramping up the dose to achieve\u00a0a therapeutic effect. Valproate toxicity may also occur when free or unbound drug levels become elevated. Elevated free drug concentrations are\u00a0common\u00a0in older patients and patients with hypoalbuminemia, and also in those who are pregnant, have renal dysfunction, liver disease, or in those who use medications that compete with valproate for albumin binding sites. [3] Additionally, patients who intentionally overdose on valproate during attempts of\u00a0self harm\u00a0experience varying degrees of valproate toxicity. [4]"}
{"id": "article-30391_6", "title": "Valproate Toxicity -- Epidemiology", "content": "According to the American Association of Poison Control Centers' National Poison Data System, cases of acute ingestion of valproate increased from 2717 in 1994 to 8705 in 2005. [5] More recently, cases of acute ingestion of valproate cases have stabilized. There were 3211 cases of acute valproate ingestion in 2010 and 2996 cases in 2018. [6] Children may be at particular risk for valproate toxicity, though it can occur in patients of all ages. [7]", "contents": "Valproate Toxicity -- Epidemiology. According to the American Association of Poison Control Centers' National Poison Data System, cases of acute ingestion of valproate increased from 2717 in 1994 to 8705 in 2005. [5] More recently, cases of acute ingestion of valproate cases have stabilized. There were 3211 cases of acute valproate ingestion in 2010 and 2996 cases in 2018. [6] Children may be at particular risk for valproate toxicity, though it can occur in patients of all ages. [7]"}
{"id": "article-30391_7", "title": "Valproate Toxicity -- Pathophysiology", "content": "Patients with valproate toxicity commonly experience hyperammonemia, encephalopathy, and hepatotoxicity. [8] Valproate\u00a0decreases tissue carnitine levels, which results in microvesicular steatosis and hyperammonemia. [9] [10] Valproate-induced encephalopathy is typically related to the effects of hyperammonemia. However, valproate-induced cerebral edema\u00a0may also\u00a0be impacted\u00a0by altered valproate metabolism, which allows the presence of toxic drug metabolites to enter the brain. [8] [11] Valproate-induced hepatotoxicity is likely due to\u00a0inhibiting beta-oxidation of fatty acids, which results in mitochondrial injury.", "contents": "Valproate Toxicity -- Pathophysiology. Patients with valproate toxicity commonly experience hyperammonemia, encephalopathy, and hepatotoxicity. [8] Valproate\u00a0decreases tissue carnitine levels, which results in microvesicular steatosis and hyperammonemia. [9] [10] Valproate-induced encephalopathy is typically related to the effects of hyperammonemia. However, valproate-induced cerebral edema\u00a0may also\u00a0be impacted\u00a0by altered valproate metabolism, which allows the presence of toxic drug metabolites to enter the brain. [8] [11] Valproate-induced hepatotoxicity is likely due to\u00a0inhibiting beta-oxidation of fatty acids, which results in mitochondrial injury."}
{"id": "article-30391_8", "title": "Valproate Toxicity -- Toxicokinetics", "content": "In the United States, oral valproate\u00a0formulations include\u00a0valproic acid, sodium valproate, and divalproex. Valproic acid and sodium valproate are immediate-release formulations,\u00a0while divalproex\u00a0is formulated\u00a0as delayed- or extended-release. Valproate\u00a0is also formulated\u00a0for intravenous use as sodium valproate. [12] The liver metabolizes valproate primarily through\u00a0glucuronide conjugation and beta-oxidation. The average elimination half-life of valproate is approximately 11 hours. [13] However, the elimination\u00a0half-life of valproate can increase to 30 or more hours in the setting of acute overdose despite elimination via first-order kinetics. [14] In the setting of valproate toxicity, a greater degree of omega-oxidation occurs in the liver, which increases the risk of hepatotoxicity, cerebral edema, and hyperammonemia. [11] Cytochrome P (CYP)2C9 and CYP2A6 enzymes also play a role in valproate metabolism. Results from a recently published meta-analysis showed that patients with\u00a0CYP2C9*3 and CYP2A6*4 genotype variants had higher serum valproate concentrations than patients without. [15]", "contents": "Valproate Toxicity -- Toxicokinetics. In the United States, oral valproate\u00a0formulations include\u00a0valproic acid, sodium valproate, and divalproex. Valproic acid and sodium valproate are immediate-release formulations,\u00a0while divalproex\u00a0is formulated\u00a0as delayed- or extended-release. Valproate\u00a0is also formulated\u00a0for intravenous use as sodium valproate. [12] The liver metabolizes valproate primarily through\u00a0glucuronide conjugation and beta-oxidation. The average elimination half-life of valproate is approximately 11 hours. [13] However, the elimination\u00a0half-life of valproate can increase to 30 or more hours in the setting of acute overdose despite elimination via first-order kinetics. [14] In the setting of valproate toxicity, a greater degree of omega-oxidation occurs in the liver, which increases the risk of hepatotoxicity, cerebral edema, and hyperammonemia. [11] Cytochrome P (CYP)2C9 and CYP2A6 enzymes also play a role in valproate metabolism. Results from a recently published meta-analysis showed that patients with\u00a0CYP2C9*3 and CYP2A6*4 genotype variants had higher serum valproate concentrations than patients without. [15]"}
{"id": "article-30391_9", "title": "Valproate Toxicity -- Toxicokinetics", "content": "Very little valproate\u00a0is excreted\u00a0in the urine as an unchanged drug. Aspirin increases free serum valproate levels by competing for plasma protein binding sites. Hypoalbuminemia, a condition common in patients who are older and in those with liver disease, also increases free serum valproate\u00a0levels. Because total valproate serum levels may remain constant despite alterations in protein binding, measuring free or unbound serum levels is best practice in the setting of valproate toxicity. [16]", "contents": "Valproate Toxicity -- Toxicokinetics. Very little valproate\u00a0is excreted\u00a0in the urine as an unchanged drug. Aspirin increases free serum valproate levels by competing for plasma protein binding sites. Hypoalbuminemia, a condition common in patients who are older and in those with liver disease, also increases free serum valproate\u00a0levels. Because total valproate serum levels may remain constant despite alterations in protein binding, measuring free or unbound serum levels is best practice in the setting of valproate toxicity. [16]"}
{"id": "article-30391_10", "title": "Valproate Toxicity -- History and Physical", "content": "When assessing a patient with suspected valproate toxicity, clinicians should\u00a0ascertain the specific time of valproate ingestion, valproate formulation, the amount of valproate ingested, other possible coingestants (eg, acetaminophen or alcohol), and a list of all of the patient's prior psychiatric or medical problems. Patients with acute ingestion of 200 mg/kg of valproate or serum valproate concentrations\u00a0of 180 mg/L or greater often\u00a0experience\u00a0central nervous system dysfunction. Manifestations of central nervous system dysfunction include tremors, agitation, miosis, and other focal neurological deficits. Patients who experience valproate-related hyperammonemic encephalopathy may experience confusion, seizures, and lethargy, which\u00a0can progress to stupor, coma, and death. [17] [18] Additionally, patients with valproate toxicity may experience respiratory depression, hypotension, and tachycardia.\u00a0Gastrointestinal symptoms consistent with valproate toxicity include vomiting, diarrhea, and abdominal pain. [11]", "contents": "Valproate Toxicity -- History and Physical. When assessing a patient with suspected valproate toxicity, clinicians should\u00a0ascertain the specific time of valproate ingestion, valproate formulation, the amount of valproate ingested, other possible coingestants (eg, acetaminophen or alcohol), and a list of all of the patient's prior psychiatric or medical problems. Patients with acute ingestion of 200 mg/kg of valproate or serum valproate concentrations\u00a0of 180 mg/L or greater often\u00a0experience\u00a0central nervous system dysfunction. Manifestations of central nervous system dysfunction include tremors, agitation, miosis, and other focal neurological deficits. Patients who experience valproate-related hyperammonemic encephalopathy may experience confusion, seizures, and lethargy, which\u00a0can progress to stupor, coma, and death. [17] [18] Additionally, patients with valproate toxicity may experience respiratory depression, hypotension, and tachycardia.\u00a0Gastrointestinal symptoms consistent with valproate toxicity include vomiting, diarrhea, and abdominal pain. [11]"}
{"id": "article-30391_11", "title": "Valproate Toxicity -- History and Physical", "content": "Interestingly, the dermatohistopathology of valproate toxicity has\u00a0been consistent\u00a0with cases of hypersensitivity vasculitis and psoriasiform eruption. Patients\u00a0on chronic valproate therapy\u00a0may also exhibit symptoms consistent\u00a0with alopecia due to telogen effluvium, including diffuse hair loss, thinning, and graying. [19] Valproate is also a potential teratogen. Fetal exposure\u00a0to valproate during pregnancy\u00a0can result in a wide range of congenital malformations, including\u00a0spina bifida, anencephaly, craniofacial abnormalities, and genitourinary defects. [20]", "contents": "Valproate Toxicity -- History and Physical. Interestingly, the dermatohistopathology of valproate toxicity has\u00a0been consistent\u00a0with cases of hypersensitivity vasculitis and psoriasiform eruption. Patients\u00a0on chronic valproate therapy\u00a0may also exhibit symptoms consistent\u00a0with alopecia due to telogen effluvium, including diffuse hair loss, thinning, and graying. [19] Valproate is also a potential teratogen. Fetal exposure\u00a0to valproate during pregnancy\u00a0can result in a wide range of congenital malformations, including\u00a0spina bifida, anencephaly, craniofacial abnormalities, and genitourinary defects. [20]"}
{"id": "article-30391_12", "title": "Valproate Toxicity -- Evaluation", "content": "Therapeutic serum concentrations of valproate usually range from 50 to 100 mg/L. Valproate levels should be obtained every 2\u00a0to 4 hours for patients with suspected valproate toxicity and until the serum valproate level starts declining. A steady decline in the level suggests a peak serum level has\u00a0been reached. [21] Unbound valproate levels are an assessment tool in patients who are\u00a0hypoalbuminemic,\u00a0or when signs of valproate toxicity are present despite low or normal total valproate levels. [16]", "contents": "Valproate Toxicity -- Evaluation. Therapeutic serum concentrations of valproate usually range from 50 to 100 mg/L. Valproate levels should be obtained every 2\u00a0to 4 hours for patients with suspected valproate toxicity and until the serum valproate level starts declining. A steady decline in the level suggests a peak serum level has\u00a0been reached. [21] Unbound valproate levels are an assessment tool in patients who are\u00a0hypoalbuminemic,\u00a0or when signs of valproate toxicity are present despite low or normal total valproate levels. [16]"}
{"id": "article-30391_13", "title": "Valproate Toxicity -- Evaluation", "content": "Other\u00a0important\u00a0laboratory\u00a0tests to order for patients with suspected valproate toxicity\u00a0include a complete blood count with differential. If the patient is experiencing valproate toxicity, thrombocytopenia, and decreased granulocyte counts may be present. Additionally, a comprehensive metabolic panel is helpful to assess the patient for hypoglycemia, hepatotoxicity, electrolyte abnormalities, and acid-base disorders. Blood ammonia levels should\u00a0be studied\u00a0for patients experiencing encephalopathy.\u00a0Toxicologic screening for\u00a0coingestants, including other anticonvulsants, aspirin, and\u00a0acetaminophen\u00a0should also considered.\u00a0A pregnancy test should\u00a0be ordered\u00a0for women of childbearing age. [21]", "contents": "Valproate Toxicity -- Evaluation. Other\u00a0important\u00a0laboratory\u00a0tests to order for patients with suspected valproate toxicity\u00a0include a complete blood count with differential. If the patient is experiencing valproate toxicity, thrombocytopenia, and decreased granulocyte counts may be present. Additionally, a comprehensive metabolic panel is helpful to assess the patient for hypoglycemia, hepatotoxicity, electrolyte abnormalities, and acid-base disorders. Blood ammonia levels should\u00a0be studied\u00a0for patients experiencing encephalopathy.\u00a0Toxicologic screening for\u00a0coingestants, including other anticonvulsants, aspirin, and\u00a0acetaminophen\u00a0should also considered.\u00a0A pregnancy test should\u00a0be ordered\u00a0for women of childbearing age. [21]"}
{"id": "article-30391_14", "title": "Valproate Toxicity -- Evaluation", "content": "Other tests to\u00a0consider include\u00a0a  12-lead echocardiogram that shows an atrioventricular conduction block. [22] Sometimes, severe valproate toxicity is associated with atrial tachycardia. [23] A computed tomography scan of the head\u00a0is necessary when patients present with signs of focal neurological deficits, profound central nervous system depression, or suspicion of cerebral edema. [19]", "contents": "Valproate Toxicity -- Evaluation. Other tests to\u00a0consider include\u00a0a  12-lead echocardiogram that shows an atrioventricular conduction block. [22] Sometimes, severe valproate toxicity is associated with atrial tachycardia. [23] A computed tomography scan of the head\u00a0is necessary when patients present with signs of focal neurological deficits, profound central nervous system depression, or suspicion of cerebral edema. [19]"}
{"id": "article-30391_15", "title": "Valproate Toxicity -- Treatment / Management", "content": "Initial therapy for patients with valproate toxicity should focus on medical stabilization and resuscitation. Specifically, initial interventions should focus on maintaining the airway, breathing, and circulation.\u00a0Patients with severe respiratory depression may require endotracheal intubation and mechanical ventilation.\u00a0Intravenous access may be needed to provide intravenous fluid\u00a0and vasopressors for patients presenting with hypotension.\u00a0Benzodiazepines should\u00a0be administered\u00a0if there is a seizure due to valproate toxicity. [24]", "contents": "Valproate Toxicity -- Treatment / Management. Initial therapy for patients with valproate toxicity should focus on medical stabilization and resuscitation. Specifically, initial interventions should focus on maintaining the airway, breathing, and circulation.\u00a0Patients with severe respiratory depression may require endotracheal intubation and mechanical ventilation.\u00a0Intravenous access may be needed to provide intravenous fluid\u00a0and vasopressors for patients presenting with hypotension.\u00a0Benzodiazepines should\u00a0be administered\u00a0if there is a seizure due to valproate toxicity. [24]"}
{"id": "article-30391_16", "title": "Valproate Toxicity -- Treatment / Management", "content": "Other\u00a0interventions to consider early for patients with valproate toxicity are gastrointestinal decontamination and lavage. If the patient presents within 2 hours of a valproate overdose, activated charcoal may\u00a0be used\u00a0for gastrointestinal decontamination. Valproate is available in enteric-coated and extended-release formulations, which have slow absorption. Administration of activated charcoal\u00a0may\u00a0be considered\u00a0beyond 2 hours from ingestion for\u00a0patients who have taken enteric-coated and extended-release valproate formulations. [25] The dose of activated charcoal is 1 g/kg of body weight. If the patient cannot\u00a0swallow reliably, the administration of activated charcoal should\u00a0be withheld. Gastric lavage may also\u00a0be considered\u00a0to eliminate valproate from the digestive tract. Food and Drug Administration guidelines indicate that gastric lavage treatment may be effective up to 10 or 12 hours after drug intake. [26]", "contents": "Valproate Toxicity -- Treatment / Management. Other\u00a0interventions to consider early for patients with valproate toxicity are gastrointestinal decontamination and lavage. If the patient presents within 2 hours of a valproate overdose, activated charcoal may\u00a0be used\u00a0for gastrointestinal decontamination. Valproate is available in enteric-coated and extended-release formulations, which have slow absorption. Administration of activated charcoal\u00a0may\u00a0be considered\u00a0beyond 2 hours from ingestion for\u00a0patients who have taken enteric-coated and extended-release valproate formulations. [25] The dose of activated charcoal is 1 g/kg of body weight. If the patient cannot\u00a0swallow reliably, the administration of activated charcoal should\u00a0be withheld. Gastric lavage may also\u00a0be considered\u00a0to eliminate valproate from the digestive tract. Food and Drug Administration guidelines indicate that gastric lavage treatment may be effective up to 10 or 12 hours after drug intake. [26]"}
{"id": "article-30391_17", "title": "Valproate Toxicity -- Treatment / Management", "content": "After initial stabilization, it is prudent to consider the use of L-carnitine for patients presenting with an acute overdose of valproate and altered mental status. L-carnitine should be administered intravenously with a loading dose of 100 mg/kg, followed by 50 mg/kg intravenously every 8 hours. Serum ammonia levels should be simultaneously measured, and when serum ammonia levels start decreasing, L-carnitine therapy can\u00a0be discontinued. [27] In the pediatric population, resulting evidence from a few case reports shows that carnitine may\u00a0alter the generation of potentially toxic metabolites, but it may not translate into improved clinical prognosis. [28] Interestingly, the mu-opioid receptor antagonist naloxone may reverse the central nervous system\u00a0depression in\u00a0some cases of\u00a0valproate poisoning. [29] [30] Naloxone may also be\u00a0useful\u00a0for chronic valproate intoxication. [31]", "contents": "Valproate Toxicity -- Treatment / Management. After initial stabilization, it is prudent to consider the use of L-carnitine for patients presenting with an acute overdose of valproate and altered mental status. L-carnitine should be administered intravenously with a loading dose of 100 mg/kg, followed by 50 mg/kg intravenously every 8 hours. Serum ammonia levels should be simultaneously measured, and when serum ammonia levels start decreasing, L-carnitine therapy can\u00a0be discontinued. [27] In the pediatric population, resulting evidence from a few case reports shows that carnitine may\u00a0alter the generation of potentially toxic metabolites, but it may not translate into improved clinical prognosis. [28] Interestingly, the mu-opioid receptor antagonist naloxone may reverse the central nervous system\u00a0depression in\u00a0some cases of\u00a0valproate poisoning. [29] [30] Naloxone may also be\u00a0useful\u00a0for chronic valproate intoxication. [31]"}
{"id": "article-30391_18", "title": "Valproate Toxicity -- Treatment / Management", "content": "Hemodialysis\u00a0is indicated\u00a0for serum valproate concentrations\u00a0greater\u00a0than 1300 mg/L and in patients experiencing shock or cerebral edema.\u00a0Hemodialysis can\u00a0greatly\u00a0reduce\u00a0the elimination half-life of valproate. In one case study, hemodialysis decreased\u00a0the half-life of\u00a0valproate from 13 hours to 1.7 hours. Additionally, hemodialysis contributed to significant clinical improvement for the patient within 4 hours of treatment.\u00a0Intermittent hemodialysis is the preferred technique for patients experiencing valproate toxicity, although continuous renal replacement therapy is an acceptable alternative if the patient cannot tolerate intermittent hemodialysis. Hemodialysis treatment can\u00a0be discontinued\u00a0if the serum valproate\u00a0concentration\u00a0drops below\u00a0100 mg/L and the patient\u00a0shows signs of clinical improvement, including normotension, improved mental status,\u00a0pH normalization,\u00a0and resolution of electrolyte abnormalities. [32]", "contents": "Valproate Toxicity -- Treatment / Management. Hemodialysis\u00a0is indicated\u00a0for serum valproate concentrations\u00a0greater\u00a0than 1300 mg/L and in patients experiencing shock or cerebral edema.\u00a0Hemodialysis can\u00a0greatly\u00a0reduce\u00a0the elimination half-life of valproate. In one case study, hemodialysis decreased\u00a0the half-life of\u00a0valproate from 13 hours to 1.7 hours. Additionally, hemodialysis contributed to significant clinical improvement for the patient within 4 hours of treatment.\u00a0Intermittent hemodialysis is the preferred technique for patients experiencing valproate toxicity, although continuous renal replacement therapy is an acceptable alternative if the patient cannot tolerate intermittent hemodialysis. Hemodialysis treatment can\u00a0be discontinued\u00a0if the serum valproate\u00a0concentration\u00a0drops below\u00a0100 mg/L and the patient\u00a0shows signs of clinical improvement, including normotension, improved mental status,\u00a0pH normalization,\u00a0and resolution of electrolyte abnormalities. [32]"}
{"id": "article-30391_19", "title": "Valproate Toxicity -- Differential Diagnosis", "content": "Symptoms of valproate toxicity overlap with many conditions. Thus, a detailed history, physical examination, laboratory evaluation, and cerebral imaging are required to diagnose valproate toxicity. [33] The most common symptoms of valproate toxicity are altered mental status and central nervous system depression, which can be due to a wide range of conditions. Suspicion of meningitis should arise when a patient presents with fever and neck stiffness accompanied by altered mental status.", "contents": "Valproate Toxicity -- Differential Diagnosis. Symptoms of valproate toxicity overlap with many conditions. Thus, a detailed history, physical examination, laboratory evaluation, and cerebral imaging are required to diagnose valproate toxicity. [33] The most common symptoms of valproate toxicity are altered mental status and central nervous system depression, which can be due to a wide range of conditions. Suspicion of meningitis should arise when a patient presents with fever and neck stiffness accompanied by altered mental status."}
{"id": "article-30391_20", "title": "Valproate Toxicity -- Differential Diagnosis", "content": "Herpes simplex virus-1 encephalitis\u00a0typically shows temporal lobe involvement in magnetic resonance images. Additionally, cranial neoplasm, intracranial hemorrhage, hydrocephalus, and traumatic brain injury should\u00a0be ruled out\u00a0as the cause of these symptoms.\u00a0Valproate-induced tremors occur in about 10% of patients and require differentiation from essential tremors or tremors associated with Parkinson disease.", "contents": "Valproate Toxicity -- Differential Diagnosis. Herpes simplex virus-1 encephalitis\u00a0typically shows temporal lobe involvement in magnetic resonance images. Additionally, cranial neoplasm, intracranial hemorrhage, hydrocephalus, and traumatic brain injury should\u00a0be ruled out\u00a0as the cause of these symptoms.\u00a0Valproate-induced tremors occur in about 10% of patients and require differentiation from essential tremors or tremors associated with Parkinson disease."}
{"id": "article-30391_21", "title": "Valproate Toxicity -- Differential Diagnosis", "content": "A comprehensive metabolic panel should\u00a0be ordered\u00a0to search for metabolic derangements,\u00a0including\u00a0hypoglycemia and hypernatremia. As serum ammonia is frequently elevated with valproate poisoning, disorders of urea cycle disorders and hepatic encephalopathy should merit consideration. Finally, other causes of anion gap metabolic acidosis should\u00a0be investigated. Common causes of anion gap metabolic acidosis include uremia, methanol poisoning, diabetic ketoacidosis, and lactic acidosis.", "contents": "Valproate Toxicity -- Differential Diagnosis. A comprehensive metabolic panel should\u00a0be ordered\u00a0to search for metabolic derangements,\u00a0including\u00a0hypoglycemia and hypernatremia. As serum ammonia is frequently elevated with valproate poisoning, disorders of urea cycle disorders and hepatic encephalopathy should merit consideration. Finally, other causes of anion gap metabolic acidosis should\u00a0be investigated. Common causes of anion gap metabolic acidosis include uremia, methanol poisoning, diabetic ketoacidosis, and lactic acidosis."}
{"id": "article-30391_22", "title": "Valproate Toxicity -- Prognosis", "content": "The prognosis for patients with valproate toxicity will depend on the total amount of valproate ingested, the opportunity to implement decontamination and elimination strategies, and the supportive care given. Severe ingestions may resolve without any sequelae after aggressive decontamination, elimination, and adequate supportive caIn one observational, retrospective study involving 316 patients, the\u00a0prognosis of patients with acute valproate toxicity was good with supportive care alone. According to the multivariate analysis within the study, a coma during the initial presentation\u00a0was associated\u00a0with a poor prognosis. Other poor prognostic factors include advanced age, metabolic derangements, and ingesting large amounts of valproate. [34]", "contents": "Valproate Toxicity -- Prognosis. The prognosis for patients with valproate toxicity will depend on the total amount of valproate ingested, the opportunity to implement decontamination and elimination strategies, and the supportive care given. Severe ingestions may resolve without any sequelae after aggressive decontamination, elimination, and adequate supportive caIn one observational, retrospective study involving 316 patients, the\u00a0prognosis of patients with acute valproate toxicity was good with supportive care alone. According to the multivariate analysis within the study, a coma during the initial presentation\u00a0was associated\u00a0with a poor prognosis. Other poor prognostic factors include advanced age, metabolic derangements, and ingesting large amounts of valproate. [34]"}
{"id": "article-30391_23", "title": "Valproate Toxicity -- Complications", "content": "Acute valproate toxicity can result in dose-related and reversible hepatotoxicity. Usually, ceasing the drug therapy results in the normalization of liver function abnormalities, but fulminant\u00a0hepatic failure and death have\u00a0been reported\u00a0with valproate toxicity. [35] [36] Concerningly, liver transplants in children with valproate-induced acute hepatic failure have reduced survival rates compared to liver transplants from other causes of drug-induced liver injury. [37] Cerebral edema may lead to herniation, prolonged central nervous system depression, and coma. [11] [14] Valproate-related hyperammonemic encephalopathy can lead to\u00a0confusion, lethargy, and increased seizure frequency. If severe valproate toxicity is untreated, death may result. [38] [39]", "contents": "Valproate Toxicity -- Complications. Acute valproate toxicity can result in dose-related and reversible hepatotoxicity. Usually, ceasing the drug therapy results in the normalization of liver function abnormalities, but fulminant\u00a0hepatic failure and death have\u00a0been reported\u00a0with valproate toxicity. [35] [36] Concerningly, liver transplants in children with valproate-induced acute hepatic failure have reduced survival rates compared to liver transplants from other causes of drug-induced liver injury. [37] Cerebral edema may lead to herniation, prolonged central nervous system depression, and coma. [11] [14] Valproate-related hyperammonemic encephalopathy can lead to\u00a0confusion, lethargy, and increased seizure frequency. If severe valproate toxicity is untreated, death may result. [38] [39]"}
{"id": "article-30391_24", "title": "Valproate Toxicity -- Consultations", "content": "A poison control center should always\u00a0be consulted\u00a0when a patient presents with valproate toxicity. Contact with a poison control center is critical when the diagnosis of valproate toxicity is unclear or if the patient is critically ill.\u00a0A\u00a0nephrology consultation and consideration for hemodialysis\u00a0is recommended\u00a0when valproate toxicity\u00a0is accompanied\u00a0by cerebral edema or shock or if the serum valproate concentration is more than 1300 mg/L. [32] All patients with intentional valproate overdose also require consultation with a psychiatrist.", "contents": "Valproate Toxicity -- Consultations. A poison control center should always\u00a0be consulted\u00a0when a patient presents with valproate toxicity. Contact with a poison control center is critical when the diagnosis of valproate toxicity is unclear or if the patient is critically ill.\u00a0A\u00a0nephrology consultation and consideration for hemodialysis\u00a0is recommended\u00a0when valproate toxicity\u00a0is accompanied\u00a0by cerebral edema or shock or if the serum valproate concentration is more than 1300 mg/L. [32] All patients with intentional valproate overdose also require consultation with a psychiatrist."}
{"id": "article-30391_25", "title": "Valproate Toxicity -- Deterrence and Patient Education", "content": "On discharge, the patient\u00a0should\u00a0receive counsel that\u00a0liver problems can happen with valproate overdose, which can be fatal. Parents need to know that children\u00a0under\u00a02\u00a0years old are at higher risk of deadly liver problems, including\u00a0Alpers\u2013Huttenlocher syndrome. [37] Pregnant\u00a0women\u00a0should be educated that valproate may cause severe congenital disabilities, including spina bifida and neurodevelopmental disorders, and that contraception should\u00a0be used\u00a0if women are sexually active while taking valproate. [20] Patients should also be informed of the risk of pancreatitis with long-term therapy. Specifically, patients should\u00a0be advised\u00a0to immediately contact their clinician or an emergency department if they develop symptoms such as acute abdominal pain, nausea, vomiting, or fever. [40]", "contents": "Valproate Toxicity -- Deterrence and Patient Education. On discharge, the patient\u00a0should\u00a0receive counsel that\u00a0liver problems can happen with valproate overdose, which can be fatal. Parents need to know that children\u00a0under\u00a02\u00a0years old are at higher risk of deadly liver problems, including\u00a0Alpers\u2013Huttenlocher syndrome. [37] Pregnant\u00a0women\u00a0should be educated that valproate may cause severe congenital disabilities, including spina bifida and neurodevelopmental disorders, and that contraception should\u00a0be used\u00a0if women are sexually active while taking valproate. [20] Patients should also be informed of the risk of pancreatitis with long-term therapy. Specifically, patients should\u00a0be advised\u00a0to immediately contact their clinician or an emergency department if they develop symptoms such as acute abdominal pain, nausea, vomiting, or fever. [40]"}
{"id": "article-30391_26", "title": "Valproate Toxicity -- Enhancing Healthcare Team Outcomes", "content": "To\u00a0improve\u00a0patient-centered care and outcomes related to valproate toxicity, physicians, advanced practice providers, nurses, pharmacists, and other health professionals must develop comprehensive skills and strategies. Physicians and advanced practice providers should identify risk factors,\u00a0apply their expertise in assessing patients for signs of overdose, implement appropriate interventions, and coordinate multidisciplinary care.", "contents": "Valproate Toxicity -- Enhancing Healthcare Team Outcomes. To\u00a0improve\u00a0patient-centered care and outcomes related to valproate toxicity, physicians, advanced practice providers, nurses, pharmacists, and other health professionals must develop comprehensive skills and strategies. Physicians and advanced practice providers should identify risk factors,\u00a0apply their expertise in assessing patients for signs of overdose, implement appropriate interventions, and coordinate multidisciplinary care."}
{"id": "article-30391_27", "title": "Valproate Toxicity -- Enhancing Healthcare Team Outcomes", "content": "Nurses are crucial in monitoring patients and providing supportive care during stabilization and resuscitation. Pharmacists should ensure accurate medication management and dosing adjustments.\u00a0Effective interprofessional communication among team members is essential for sharing critical information, interpreting laboratory results, and making timely decisions regarding treatment modalities like L-carnitine and hemodialysis. Care coordination efforts should prioritize patient safety and optimize team performance, ultimately improving outcomes for patients experiencing valproate toxicity.", "contents": "Valproate Toxicity -- Enhancing Healthcare Team Outcomes. Nurses are crucial in monitoring patients and providing supportive care during stabilization and resuscitation. Pharmacists should ensure accurate medication management and dosing adjustments.\u00a0Effective interprofessional communication among team members is essential for sharing critical information, interpreting laboratory results, and making timely decisions regarding treatment modalities like L-carnitine and hemodialysis. Care coordination efforts should prioritize patient safety and optimize team performance, ultimately improving outcomes for patients experiencing valproate toxicity."}
{"id": "article-30391_28", "title": "Valproate Toxicity -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Valproate Toxicity -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}